Trailing a big-selling rival from Pfizer and Bristol Myers Squibb, Bayer and Johnson & Johnson are looking for any opportunity to bolster their aging heart drug Xarelto. Now, just short of its 10th ...
NEW YORK - U.S. health regulators have again declined to approve proposed wider uses of Bayer AG and Johnson & Johnson's lucrative blood clot preventer Xarelto, the drugmakers said on Friday. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results